12 month embargo at publisher's request.. Restriction lift date: 2017-09-23
Genetic medicines for CF: hype versus reality
Loading...
Files
Accepted Version
Date
2016-09-23
Authors
Alton, Eric W. F. W.
Boyd, A. Christopher
Davies, Jane C.
Gill, Deborah R.
Griesenbach, Uta
Harrison, Patrick T.
Henig, Noreen
Higgins, Tracy
Hyde, Stephen C.
Innes, J. Alastair
Journal Title
Journal ISSN
Volume Title
Publisher
Wiley
Published Version
Abstract
Since identification of the CFTR gene over 25 years ago, gene therapy for cystic fibrosis (CF) has been actively developed. More recently gene therapy has been joined by other forms of “genetic medicines” including mRNA delivery, as well as genome editing and mRNA repair-based strategies. Proof-of-concept that gene therapy can stabilize the progression of CF lung disease has recently been established in a Phase IIb trial. An early phase study to assess the safety and explore efficacy of CFTR mRNA repair is ongoing, while mRNA delivery and genome editing-based strategies are currently at the pre-clinical phase of development. This review has been written jointly by some of those involved in the various CF “genetic medicine” fields and will summarize the current state-of-the-art, as well as discuss future developments. Where applicable, it highlights common problems faced by each of the strategies, and also tries to highlight where a specific strategy may have an advantage on the pathway to clinical translation. We hope that this review will contribute to the ongoing discussion about the hype versus reality of genetic medicine-based treatment approaches in CF.
Description
Keywords
Cystic fibrosis (CF) , Gene therapy , Genome editing , Lung
Citation
Alton, E. W. F. W., Boyd, A. C., Davies, J. C., Gill, D. R., Griesenbach, U., Harrison, P. T., Henig, N., Higgins, T., Hyde, S. C., Innes, J. A. & Korman, M. S. D. (2016) ‘Genetic medicines for CF: hype versus reality’, Pediatric Pulmonology, 51(S44), pp. S5-S17. doi: 10.1002/ppul.23543
Link to publisher’s version
Collections
Copyright
© 2016 Wiley Periodicals, Inc. This is the peer reviewed version of the following article: Alton, et al., ‘Genetic medicines for CF: hype versus reality’, Pediatr Pulmonol., 51: S5–S17, which has been published in final form at http://dx.doi.org/10.1002/ppul.23543. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.